Abstract

IPR , BOISAFETY AND REGULATORY FRAME WORK FOR PHARMA INDUSTRIES

Abstract IPR, Biosafety and Bioethics covers a broad coverage of three areas of patenting--intellectual property rights (IPR), biosafety and bioethics. Intellectual Property Rights are the rights given to persons over the creations of their minds. Types of Intellectual property rights (IPR) such as copyright, patent, trademarks, industrial designs, trade secrets, geographical indications and so on are meant to protect creators of new inventions, their families and consumers. Strong IP rights help consumers make an educated choice about the safety, reliability, and effectiveness of their purchases. Enforced IP rights ensure that products are authentic, and of the high-quality that consumers recognize and accept. Biosafety is meant to create an appropriate bio safe working environment to protect workers from laboratory-induced infections who work with deadly disease-causing microorganisms such as the present pandemic Covid -19 virus, for their characterization, diagnostics or therapeutics and vaccine development purposes which are posing increasingly potential biosafety problems for healthcare personnel and laboratory workers. Bioethics is the typically controversial ethical issues emerging from new situations and possibilities brought about by advances in biology and medicine. Regulatory Frame Work : India is home to about 10,500 manufacturing units and over 3,000 pharma companies. India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines. The growth of pharmaceutical market depends upon various factors including regulatory legislations and drug regulatory system. Two major government agencies responsible for drug regulation and control are: 1) the Drugs Controller of India (DCI), and 2) the State Food and Drug Administrations (FDAs). The DCI, under the Ministry of Health, has five main functions: 1) Controlling the quality of imported drugs, 2) Coordinating the activities of State FDAs, 3) Enforcing new drug legislation, 4) Granting approval to new drugs, and 5) Controlling the quality of imported drugs. The present paper highlights IPR and some of the risks & regulations of biosafety for pharma industries


Author(s): philomena george

Abstract | PDF

Share This Article
Awards Nomination 17+ Million Readerbase
Google Scholar citation report
Citations : 4713

Der Pharmacia Sinica received 4713 citations as per Google Scholar report

Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Proquest Summons
  • MIAR
  • International Committee of Medical Journal Editors (ICMJE)
  • Serials Union Catalogue (SUNCAT)
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs
  • CAS (Chemical Abstracting Services)
  • University of Barcelona

View More »

Flyer image